Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau Imaging Substudy in UAB Alzheimer's Disease Center Core Cohort
NCT03809351Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jul 2020
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flortaucipir in Alzheimer's disease (AD), sponsored by University of Alabama at Birmingham. Primary endpoint: Measurement of pathological tau deposition in the brain at 5 years. Started Jul 2020; status: recruiting.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03809351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809351.